Abstract:BackgroundJaundice is a common symptom of inherited or acquired liver diseases or a manifestation of diseases involving red blood cell metabolism. Recent progress has elucidated the molecular mechanisms of bile metabolism, hepatocellular transport, bile ductular development, intestinal bile salt reabsorption, and the regulation of bile acids homeostasis.Main bodyThe major genetic diseases causing jaundice involve disturbances of bile flow. The insufficiency of bile salts in the intestines leads to fat malabsorption and fat-soluble vitamin deficiencies. Accumulation of excessive bile acids and aberrant metabolites results in hepatocellular injury and biliary cirrhosis. Progressive familial intrahepatic cholestasis (PFIC) is the prototype of genetic liver diseases manifesting jaundice in early childhood, progressive liver fibrosis/cirrhosis, and failure to thrive. The first three types of PFICs identified (PFIC1, PFIC2, and PFIC3) represent defects in FIC1 (ATP8B1), BSEP (ABCB11), or MDR3 (ABCB4). In the last 5 years, new genetic disorders, such as TJP2, FXR, and MYO5B defects, have been demonstrated to cause a similar PFIC phenotype. Inborn errors of bile acid metabolism also cause progressive cholestatic liver injuries. Prompt differential diagnosis is important because oral primary bile acid replacement may effectively reverse liver failure and restore liver functions. DCDC2 is a newly identified genetic disorder causing neonatal sclerosing cholangitis. Other cholestatic genetic disorders may have extra-hepatic manifestations, such as developmental disorders causing ductal plate malformation (Alagille syndrome, polycystic liver/kidney diseases), mitochondrial hepatopathy, and endocrine or chromosomal disorders. The diagnosis of genetic liver diseases has evolved from direct sequencing of a single gene to panel-based next generation sequencing. Whole exome sequencing and whole genome sequencing have been actively investigated in research and clinical studies. Current treatment modalities include medical treatment (ursodeoxycholic acid, cholic acid or chenodeoxycholic acid), surgery (partial biliary diversion and liver transplantation), symptomatic treatment for pruritus, and nutritional therapy. New drug development based on gene-specific treatments, such as apical sodium-dependent bile acid transporter (ASBT) inhibitor, for BSEP defects are underway.Short conclusionUnderstanding the complex pathways of jaundice and cholestasis not only enhance insights into liver pathophysiology but also elucidate many causes of genetic liver diseases and promote the development of novel treatments.

The research advancement of pathogenesis of intrahepatic cholestasis jaundice related to chronic hepatits B

[Research Advances in Diagnosis and Treatment of Liver Failure in 2016].

The role of enterohepatic circulation of bile acids and intestinal microbiota in the pathogenesis and treatment of cholestatic liver disease

Advances in diagnosis and treatment of primary biliary cholangitis

Molecular Mechanisms of Hepatobiliary and Pancreatic Diseases in Patients with Inflammatory Bowel Disease

Current Status of Cholestasis: Pathogenesis, Diagnosis and Treatment

Pathogenesis of Cholestasis-Induced Liver Fibrosis and Thoughts for Blockade

Recent Advances in the Research of Immunologic Pathogenesis in Chronic Severe Hepatitis B

Advances in study on pathogenesis of hepatitis B virus-associated intrahepatic cholangiocarcinoma

An Insight into the Mechanism and Molecular Basis of Dysfunctional Immune Response Involved in Cholestasis.

Acute-on-chronic Liver Failure in Chronic Hepatitis B: an Update.

Advance in the research on several nuclear receptors related to bile acid metabolism

Advances of researches in the pathogenesis of severe hepatitis B]

Research progress on primary biliary cirrhosis

Anti-inflammatory, Anti-Oxidative Stress and Novel Therapeutic Targets for Cholestatic Liver Injury

Bile acid restrained T cell activation explains cholestasis aggravated hepatitis B virus infection

Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases

Genetic alterations and molecular mechanisms underlying hereditary intrahepatic cholestasis

Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease

Bile acid-mediated signaling in cholestatic liver diseases

Research Progress in Host Immune Response During Hepatitis B Virus Infection